Skip to content

Home
About Prostate Cancer
Treatment
Columns
- Living & Loving with Prostate Cancer
- Rick’s Prostate Column
COVID-19 Info
- COVID-19 Updates

Search for:

Second-line therapy

January 27, 2019February 6, 2020

Xtandi Should Follow Zytiga for Treatment of Castration-resistant Prostate Cancer, Phase 2 Trial Shows

News

More men with castration-resistant prostate cancer saw their prostate cancer antigen (PSA) levels — a marker of the disease — decline when they took Xtandi (enzalutamide) after Zytiga (abiraterone acetate) ... Read more

Search for:

Recent Posts

Cancer-sniffing Dogs May Help Train Robot Noses to Detect Tumors Early

February 25, 2021
Prolaris Test Helps ID Higher-risk Patients Who May Safely Skip ADT

February 23, 2021
Erleada-Zytiga Combo Delays Progression in mCRPC Patients, Phase 3 Trial Reports

February 18, 2021

Featured Posts

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

June 30, 2020

Relugolix Granted FDA Priority Review as New Treatment Type

June 25, 2020

U.K. Study to Examine Genetic Screening for Large Prostate Cancer Population

June 9, 2020

Visit Prostate Cancer News Today's profile on Pinterest.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Email: info@Bionews.com
Phone: +1-800-936-1363

Publishing Team
Leadership
Our Values
Corrections Policy
Contact Us
Terms of Service
Privacy Policy

Disclaimer:

Prostate Cancer News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 Proudly powered by WordPress | Binder PRO Theme by QuadroIdeas